newsfilter
← Latest News
Business Wire·

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Grew full-year revenue to between $515 million and $517 million, an increase of 16% Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the